End Points | Epoetin alfa-epbx, n=306^{} | Epoetin alfa, n=306 | P Value |
---|---|---|---|

Patients with mean weekly hemoglobin level within 9.0−11.0 g/dl at week 24,^{b} n/N (%) | 188/257 (73.2) | 185/259 (71.4) | 0.69 |

Patients who received a red blood cell transfusion at any time during the 24-wk treatment period,^{c} n/N (%) | 19/303 (6.3) | 18/305 (5.9) | 0.87 |

↵a Secondary efficacy end points were analyzed using the intent-to-treat population.

↵b Percentages were calculated using the number of observations at week 24 within a treatment group as the denominator.

↵c Percentages were calculated using the number of patients participating in the trial at any time during the treatment period within a treatment group as the denominator.